Pharmaceutical Commerce
OCTOBER 24, 2024
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, forecasts how cyber threats could potentially evolve over the next decade.
Bio Pharma Dive
OCTOBER 24, 2024
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its commercial outlook.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 24, 2024
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
Bio Pharma Dive
OCTOBER 24, 2024
The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell has opted to end development of two current pipeline programs.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 24, 2024
Nitrosamines are organic compounds that have gained attention in the pharma industry as impurities in manufacturing.
Bio Pharma Dive
OCTOBER 24, 2024
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 24, 2024
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
Pharma Times
OCTOBER 24, 2024
danicopan shown to improve haemoglobin levels and reduce anaemia
Bio Pharma Dive
OCTOBER 24, 2024
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple shots on the market and in development.
XTalks
OCTOBER 24, 2024
World Psoriasis Day on October 29 shines a light on this chronic autoimmune condition, aiming to increase awareness and improve access to care. Hosted by the International Federation of Psoriasis Associations (IFPA), the World Psoriasis Day 2024 theme , “Psoriatic Disease and Family,” focuses on ensuring equal treatment opportunities worldwide, with an emphasis on improving diagnosis, treatment and support for psoriasis patients.
Bio Pharma Dive
OCTOBER 24, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
Pharmaceutical Technology
OCTOBER 24, 2024
The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage.
pharmaphorum
OCTOBER 24, 2024
UK scheme to tackle "historically low" numbers of people taking part in dementia trials launches with £20m in government funding
Pharmaceutical Technology
OCTOBER 24, 2024
The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
OCTOBER 24, 2024
Results from two phase 3 trials show that GSK’s RSV vaccine Arexvy excelled in a broad age range of immunocompromised and other at-risk patients.
Pharmaceutical Technology
OCTOBER 24, 2024
At CPHI Europe, an expert discussed the significance of implementing effective AI strategies to improve nutraceutical products.
Rethinking Clinical Trials
OCTOBER 24, 2024
The NIH Pragmatic Trials Collaboratory is pleased to welcome APA-SM (Personalized Auricular Point Acupressure for Chronic Pain Self-Management in Rural Populations) to its portfolio of innovative NIH Collaboratory Trials. The new project is supported by an award from the National Institute of Neurological Disorders and Stroke, with administrative oversight from the National Center for Complementary and Integrative Health.
Pharmaceutical Technology
OCTOBER 24, 2024
Chronic myeloid leukaemia – CML – is difficult to monitor and manage using traditional solutions. New RNA-based assays are helping.
Fierce Pharma
OCTOBER 24, 2024
It’s déjà vu for Marnius Pharmaceuticals. | The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a cost-cutting scramble as it moves to explore "strategic alternatives.
Pharmaceutical Technology
OCTOBER 24, 2024
The opioid addiction treatment market will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.
pharmaphorum
OCTOBER 24, 2024
WhatsApp message earns Moderna a reprimand under the ABPI Code, with Novo Nordisk, Otsuka, AstraZeneca and Daiichi Sankyo also breaching the rules
Pharmaceutical Technology
OCTOBER 24, 2024
MSD has acquired cancer therapeutics developer Modifi Biosciences, enhancing its portfolio with preclinical compounds.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
OCTOBER 24, 2024
Biopharmaceutical solutions organization Syneos Health has announced the appointment of Costa Panagos as its new Chief Executive Officer (CEO). Panagos, an industry veteran with extensive experience in the healthcare and life sciences sector, takes over from Colin Shannon, who served as CEO for one year following the company’s acquisition by a consortium of private equity firms.
Pharmaceutical Technology
OCTOBER 24, 2024
Double Point Ventures (DPV) has entered a definitive merger agreement to acquire all outstanding shares of Lumos for $38m.
pharmaphorum
OCTOBER 24, 2024
Legal win leads Amgen to at-risk launch of Eylea biosimilar Phil.
Pharmaceutical Technology
OCTOBER 24, 2024
TreeFrog has entered a research collaboration with the University of Pittsburgh to investigate the role of TLS in immuno-oncology.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 24, 2024
Hyntelo offers cutting-edge AI solutions like GenAI for enhanced customer engagement. Learn how Hyntelo integrates as a Veeva AI Partner.
Pharmaceutical Technology
OCTOBER 24, 2024
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
pharmaphorum
OCTOBER 24, 2024
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.
Pharmaceutical Technology
OCTOBER 24, 2024
There are already two FDA-approved gene therapies for haemophilia B courtesy of Pfizer and CSL Behring.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
64 
Let's personalize your content